d Aquaflor antibiotic for farm-raised fish. Alliances The alliances segment includes results from the company’s relationship with AstraZeneca LP (AZLP). In 2014, AstraZeneca Group Plc (AstraZeneca) exercised its option to buy the company’s interest in a subsidiary and, through it, the company’s interest in Nexium and Prilosec. As a result, as of July 1, 2014, the company no longer records equity income from AZLP and supply sales to AZLP, primarily relating to sales of Nexium and Prilosec, have terminated. Joint Ventures Sanofi Pasteur MSD: In 1994, the company and Pasteur Mérieux Connaught (Sanofi Pasteur S.A.) formed a joint venture to market human vaccines in Europe and to collaborate in the development of combination vaccines for distribution in the then-existing EU and the European Free Trade Association. The joint venture maintains a presence, directly or through affiliates or branches, in Belgium, Italy, Germany, Spain, France, Austria, Ireland, Sweden, Portugal, the Netherlands, Switzerland and the United Kingdom and through distributors in the rest of its territory. Distribution The company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The company sells its animal health products to veterinarians, distributors and animal producers. Research and Development The company’s research and development expenses were $7.2 billion in 2014. The company has various candidates under regulatory review in the United States or internationally. Keytruda is an anti-PD-1 (programmed death receptor-1) therapy under review by the European Medicines Agency (EMA) for the treatment of advanced melanoma. In September 2014, the FDA approved Keytruda at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab, and if BRAF V600 mutation positive, a BRAF inhibitor. MK-8616, Bridion (sugammadex) Injection, is an investigational agent for the reversal of neuromuscular blockade induced by rocuronium or vecuronium (neuromuscular blocking agents). Neuromuscular blockade is used in anesthesiology to induce muscle relaxation during surgery. In September 2013, the company announced that it had received a Complete Response Letter (CRL) from the FDA for the resubmission of the New Drug Application (NDA) for Bridion. V419, DTaP5-IPV-Hib-HepB, is an investigational pediatric hexavalent vaccine that the company is in the process of developing in partnership with Sanofi Pasteur under review by the FDA and the EMA. MK-3102, omarigliptin, is an investigational once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor in development for the treatment of type 2 diabetes. In 2014, the company announced that it has submitted a new drug application for omarigliptin to the Japanese Pharmaceuticals and Medical Devices Agency. Omarigliptin is in Phase 3 clinical development in the United States. MK-1986, Sivextro (tedizolid phosphate), a once-daily oxazolidinone antibiotic developed for both intravenous and oral administration for the treatment of acute bacterial skin and skin structuring infections (ABSSSI) caused by certain Gram-positive organisms, is under review by the EMA. In January 2015, Merck announced that the Committee for Medicinal Products for Human Use (the CHMP) of the EMA has adopted a positive opinion recommending approval of Sivextro for the treatment of ABSSSI in adults. MK-7625A, Zerbaxa, a combination product for the treatment of certain serious bacterial infections in adults, is under review by the EMA. In December 2014, Zerbaxa was approved by the FDA for the treatment of adults with complicated urinary tract infections caused by designated susceptible Gram-negative organisms or with complicated intra-abdominal infections caused by designated susceptible Gram-negative and Gram-positive organisms
merck & co. inc.
(MRK:New York Consolidated)
One Merck Drive
PO Box 100
Whitehouse Station, NJ 08889
|Bayer AG||€133.25 EUR||+0.46|
|GlaxoSmithKline PLC||1,572 GBp||+6.00|
|Pfizer Inc||$34.60 USD||-0.04|
|Roche Holding AG||SFr.256.60 CHF||-3.60|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.